Posted inDiabetes & Endocrinology Gastroenterology news
Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-month period.